Article metrics

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

 

Online download statistics by month:

Online download statistics by month:

No statistics are available.